Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

USA ...
Amazon Smile https://smile.amazon.com/ (bookmark)
choose MEBO RESEARCH INC
0.5% to MEBO on your purchases
(no extra cost to you)

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Monday, November 25, 2019

Gene Therapy : 1st 2 USA cases went well

Gene Therapy will likely be the ultimate cure for SUB-PAR FMO3 function ('TMAU1').
The 1st 2 cases of CRISPR Gene Therapy in the USA are happening this year.
An update this week said they were going well (after initial therapy).
The 1st 2 cases are for Genetic blood disorders.
It's likely over the years it will be good for all genetic disorders (especially single gene).

Gene Therapy quick unchecked history
pre-2012 : very difficult to do
2012 : CRISPR method makes gene knock in/out very easy and affordable. Seen as a 'T-model Ford' moment.
2019 : Base Editing method shown. Most single-gene disorders will need base editing.
2019 : First 2 cases of use in humans for single-gene disorder.

FMO3 Gene Therapy
It's unknown when FMO3 would be trialed by a health system or private company.
All the 'obvious serious' genetic disorders are ;likely to be at the front of the queue.
They still need to see how the 2 cases get on (but looking good after around 3 months).
They will need to find out delivery methods, and spend millions on research etc.
But an excellent start, and FMO3 should (in most cases) be straightforward base editing (not always).

Links

Link (New Atlas) : Encouraging early results from first human CRISPR gene therapy trials

NIH Directors Blog post
"As groundbreaking as CRISPR/Cas9 has been for editing specific genes, the system has its limitations. The initial version is best suited for making a double-stranded break in DNA, followed by error-prone repair. The outcome is generally to knock out the target. That’s great if eliminating the target is the desired goal. But what if the goal is to fix a mutation by editing it back to the normal sequence?

The new prime editing system, which was described recently by NIH-funded researchers in the journal Nature, is revolutionary because it offers much greater control for making a wide range of precisely targeted edits to the DNA code, which consists of the four “letters” (actually chemical bases) A, C, G, and T "
Link

CRISPR Therapeutics (done the 2 cases) : Press Release Link







get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

0 comments:

Post a Comment